Ionis Pharmaceuticals Inc

25. Sept. 2026, 22:20 UTC

Ionis Pharmaceuticals Inc is trading modestly higher in after-market hours, reflecting broader market gains amid mixed economic signals and rising Treasury yields.

24. Sept. 2026, 23:51 UTC

Ionis Pharmaceuticals Inc has advanced in after-market trading, recovering from an initial dip and reaching its highest point of the day.

23. Sept. 2026, 23:05 UTC

Ionis Pharmaceuticals Inc reported positive interim results from its Phase 3 IMAgINATION study, leading to a modest after-market hours increase in its stock.

22. Sept. 2026, 20:02 UTC

Ionis Pharmaceuticals shares are advancing after positive Phase 3 FUSION study results for ulefnersen, showing significant improvement in functional impairment and survival for FUS-ALS.

21. Sept. 2026, 20:06 UTC

Ionis Pharmaceuticals shares are advancing amid posts on social platforms on sales figures for TRYNGOLZA, despite earlier pulling back from a session high.

18. Sept. 2026, 20:02 UTC

Ionis Pharmaceuticals Inc shares fell sharply, trading near the lower end of their one-month range amid broader market weakness and high trading volume.

17. Sept. 2026, 20:01 UTC

Ionis Pharmaceuticals shares are higher in Thursday's session, showing unusual market volume, despite reports of its drug pelacarsen failing in a clinical trial.

16. Sept. 2026, 20:08 UTC

Ionis Pharmaceuticals shares fell amid challenges from its failed Phase 3 ATTR partnership, erasing about $4.63 billion in market value.

15. Sept. 2026, 23:01 UTC

Ionis Pharmaceuticals shares are trading higher in after-market hours, despite a broader market decline indicated by a sharp drop in the Empire State Manufacturing Index.

14. Sept. 2026, 23:16 UTC

Ionis Pharmaceuticals Inc. shares are higher in after-market trading, though still below the 20-day moving average after six consecutive sessions of declines.

11. Sept. 2026, 23:56 UTC

Ionis Pharmaceuticals received FDA approval for ZANVASTRO. Shares are higher in after-market trading, reflecting positive sentiment despite a setback in a partnered trial.

10. Sept. 2026, 19:16 UTC

Ionis Pharmaceuticals shares are lower as HC Wainwright cuts the price target from $115.00 to $100.00 while maintaining a "buy" rating.

9. Sept. 2026, 22:51 UTC

Ionis Pharmaceuticals shares are lower in after-market hours. Broader market trends reflect concerns over rising crude oil prices exceeding $100 amid Middle East tensions.

8. Sept. 2026, 23:41 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market trading, reversing earlier gains and reflecting overall weakness without any specific news to explain the decline.

5. Sept. 2026, 00:05 UTC

Ionis Pharmaceuticals shares are lower in after-market hours following Novartis' announcement that the pelacarsen Phase 3 study did not meet its primary endpoint.

4. Sept. 2026, 23:02 UTC

Ionis Pharmaceuticals shares declined in after-market trading following Novartis' announcement of the failed pelacarsen Phase 3 study to reduce cardiovascular events.

3. Sept. 2026, 22:02 UTC

Ionis Pharmaceuticals shares are higher in after-hours trading following FDA approval for Zanvastro, the first treatment for Alexander disease.

2. Sept. 2026, 23:01 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, reflecting notable selling pressure since Wednesday's close. No specific news was identified to explain the decline.

1. Sept. 2026, 22:01 UTC

Ionis Pharmaceuticals Inc shares are trading higher in after-market hours, reversing a trend of five consecutive lower sessions. No specific news was identified.

31. Aug. 2026, 19:56 UTC

Ionis Pharmaceuticals shares are lower today following negative results from a failed trial of Wainua, which did not meet its primary endpoint.

28. Aug. 2026, 21:01 UTC

Ionis Pharmaceuticals Inc. shares are lower in after-market trading, continuing a trend of four consecutive daily declines despite remaining above the 20-day moving average.

27. Aug. 2026, 23:46 UTC

Ionis Pharmaceuticals shares traded near unchanged during after-market hours, reflecting routine activity. The stock has declined for three consecutive sessions.

26. Aug. 2026, 23:51 UTC

Ionis Pharmaceuticals is rising in after-market hours, reflecting broader market gains amid positive economic data on durable goods orders and inflation indicators.

25. Aug. 2026, 23:01 UTC

Ionis Pharmaceuticals Inc shares are higher in after-market hours, maintaining momentum above the 20-day moving average amid a broader market reaction to falling crude oil prices.

24. Aug. 2026, 23:11 UTC

Ionis Pharmaceuticals shares are higher in after-market hours following a session low. Broader market performance remains subdued amid ongoing geopolitical concerns.

22. Aug. 2026, 00:01 UTC

Ionis Pharmaceuticals Inc is higher in after-market trading, reflecting strength amid a broader market rebound. The stock remains above its 20-day moving average.

21. Aug. 2026, 22:51 UTC

Ionis Pharmaceuticals Inc shares are trading higher during after-market hours, remaining above the 20-day moving average and near the upper end of their one-month range.

20. Aug. 2026, 20:02 UTC

Ionis Pharmaceuticals will present new data on hypertriglyceridemia treatments at the European Society of Cardiology Congress, though shares are trading lower today.

19. Aug. 2026, 23:06 UTC

Ionis Pharmaceuticals is advancing RG-6299 into a pivotal Phase III trial for IgA nephropathy in collaboration with Roche and Chugai. Shares are higher in after-market trading.

18. Aug. 2026, 20:06 UTC

Ionis Pharmaceuticals Inc shares are higher, supported by strong momentum above the 20-day moving average. No specific news was identified for today's move.